DNA damage checkpoint recovery and cancer development

Experimental Cell Research

Volumn 334, Issue 2, 2015, Pages 350-358

  Wang, Haiyong ^a   Zhang, Xiaoshan ^b   Teng, Lisong ^a   Legerski, Randy J ^b  

^a ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Carcinogenesis; Cell cycle checkpoints; DNA damage; Neoplasms; Oncogenes

Indexed keywords

GROWTH FACTOR; PHOSPHATASE; TUMOR PROTEIN;

CANCER GROWTH; CARCINOGENICITY; CELL CYCLE REGULATION; CELL PROLIFERATION; DNA DAMAGE CHECKPOINT; GENOTOXICITY; HUMAN; MALIGNANT TRANSFORMATION; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; REVIEW; SIGNAL TRANSDUCTION; TUMOR MODEL; ANIMAL; CELL CYCLE CHECKPOINT; DNA DAMAGE; METABOLISM; PATHOLOGY;

ONCOVIRINAE;

ANIMALS; CELL CYCLE CHECKPOINTS; DNA DAMAGE; HUMANS; NEOPLASM PROTEINS; NEOPLASMS;

EID: 84929513000     PISSN: 00144827     EISSN: 10902422     Source Type: Journal    
DOI: 10.1016/j.yexcr.2015.03.011     Document Type: Review

References (82)

1. Shiloh Y. ATM and related protein kinases: safeguarding genome integrity. Nat. Rev. Cancer 2003, 3:155-168.
2. Bartek J., Lukas J. DNA damage checkpoint: from initiation to recovery or adaptation. Curr. Opin. Cell. Biol. 2007, 19:238-245.
3. Falck J., Coates J., Jackson S.P. Conserved modes of recruitment of ATM, ATR and DNA-PKcs to sites of DNA damage. Nature 2005, 434:605-611.
4. Collins I., Garrett M.D. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Curr. Opin. Pharmacol. 2005, 5:366-373.
5. Evangelou K., Bartkova J., Kotsinas A., Pateras I.S., Liontos M., Velimezi G., Kosar M., Liloglou T., Trougakos I.P., Dyrskjot L., Andersen C.L., Papaioannou M., Drosos Y., Papafotiou G., Hodny Z., Sosa-Pineda B., Wu X.R., Klinakis A., Ørntoft T., Lukas J., Bartek J., Gorgoulis V.G. The DNA damage checkpoint precedes activation of ARF in response to escalating oncogenic stress during tumorigenesis. Cell. Death Differ. 2013, 20:1485-1497.
6. Ferbeyre G., de Stanchina E., Querido E., Baptiste N., Prives C., Lowe S.W. PML is induced by oncogenic ras and promotes premature senescence. Genes Dev. 2000, 14:2015-2027.
7. Mallette F.A., Gaumont-Leclerc M.F., Ferbeyre G. The DNA damage signaling pathway is a critical mediator of oncogene-induced senescence. Genes Dev. 2007, 21:43-48.
8. Di Micco R., Fumagalli M., Cicalese A., Piccinin S., Gasparini P., Luise C., Schurra C., Garre' M., Nuciforo P.G., Bensimon A., Maestro R., Pelicci P.G., d'Adda di Fagagna F. Oncogene-induced senescence is a DNA damage response triggered by DNA hyper-replication. Nature 2006, 444:638-642.
9. Bartkova J., Rezaei N., Liontos M., Karakaidos P., Kletsas D., Issaeva N., Vassiliou L.V., Kolettas E., Niforou K., Zoumpourlis V.C., Takaoka M., Nakagawa H., Tort F., Fugger K., Johansson F., Sehested M., Andersen C.L., Dyrskjot L., Ørntoft T., Lukas J., Kittas C., Helleday T., Halazonetis T.D., Bartek J., Gorgoulis V.G. Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 2006, 444:633-637.
10. Bartkova J., Horejsí Z., Koed K., Krämer A., Tort F., Zieger K., Guldberg P., Sehested M., Nesland J.M., Lukas C., Ørntoft T., Lukas J., Bartek J. DNA damage response as a candidate anti-cancer barrier in early human tumorigenesis. Nature 2005, 434:864-870.
11. Mukherjee S.1, Manna S., Pal D., Mukherjee P., Panda C.K. Sequential loss of cell cycle checkpoint control contributes to malignant transformation of murine embryonic fibroblasts induced by 20-methylcholanthrene. J. Cell. Physiol. 2010, 224:49-58.
12. Wallace M.D., Southard T.L., Schimenti K.J., Schimenti J.C. Role of DNA damage response pathways in preventing carcinogenesis caused by intrinsic replication stress. Oncogene 2014, 33:3688-3695.
13. Lopez-Contreras A.J., Fernandez-Capetillo.O. The ATR barrier to replication-born DNA damage. DNA Repair 2010, 9:1249-1255.
14. Smith J., Tho L.M., Xu N., Gillespie D.A. The ATM-Chk2 and ATR-Chk1 pathways in DNA damage signaling and cancer. Adv. Cancer Res. 2010, 108:73-112.
15. Tho L.M., Libertini S., Rampling R., Sansom O., Gillespie D.A. Chk1 is essential for chemical carcinogen-induced mouse skin tumorigenesis. Oncogene 2012, 31:1366-1375.
16. Sperka T., Wang J., Rudolph K.L. DNA damage checkpoints in stem cells, ageing and cancer. Nat. Rev. Mol. Cell Biol. 2012, 13:579-590.
17. Fan C., Quan R., Feng X., Gillis A., He L., Matsumoto E.D., Salama S., Cutz J.C., Kapoor A., Tang D. ATM activation is accompanied with earlier stages of prostate tumorigenesis. Biochim. Biophys. Acta 1763, 2006:1090-1097.
18. Tort F., Bartkova J., Sehested M., Orntoft T., Lukas J., Bartek J. Retinoblastoma pathway defects show differential ability to activate the constitutive DNA damage response in human tumorigenesis. Cancer Res. 2006, 66:10258-10263.
19. Bartek J., Bartkova J., Lukas J. DNA damage signalling guards against activated oncogenes and tumour progression. Oncogene 2007, 26:7773-7779.
20. Larsson L.G. Oncogene- and tumor suppressor gene-mediated suppression of cellular senescence. Semin. Cancer Biol. 2011, 21:367-376.
21. Halazonetis T.D., Gorgoulis V.G., Bartek J. An oncogene-induced DNA damage model for cancer development. Science 2008, 319:1352-1355.
22. Koganti S., Hui-Yuen J., McAllister S., Gardner B., Grasser F., Palendira U., Tangye S.G., Freeman A.F., Bhaduri-McIntosh S. STAT3 interrupts ATR-Chk1 signaling to allow oncovirus-mediated cell proliferation. Proc. Natl. Acad. Sci. USA 2014, 111:4946-4951.
23. Pellegrino R., Calvisi D.F., Ladu S., Ehemann V., Staniscia T., Evert M., Dombrowski F., Schirmacher P., Longerich T. Oncogenic and tumor suppressive roles of polo-like kinases in human hepatocellular carcinoma. Hepatology 2010, 51:857-868.
24. Yoo H.Y., Kumagai A., Shevchenko A., Shevchenko A., Dunphy W.G. Adaptation of a DNA replication checkpoint response depends upon inactivation of Claspin by the polo-like kinase. Cell 2004, 117:575-588.
25. Medema R.H., Macurek L. Checkpoint recovery in cells: how a molecular understanding can help in the fight against cancer. F1000 Biol. Rep. 2011, 3:10.
26. Clémenson C., Marsolier-Kergoat M.C. DNA damage checkpoint inactivation: adaptation and recovery. DNA Repair 2009, 8:1101-1109.
27. Chowdhury D., Keogh M.C., Ishii H., Peterson C.L., Buratowski S., Lieberman J. gamma-H2AX dephosphorylation by protein phosphatase 2A facilitates DNA double-strand break repair. Mol. Cell 2005, 20:801-809.
28. Yan Y., Cao P.T., Greer P.M., Nagengast E.S., Kolb R.H., Mumby M.C., Cowan K.H. Protein phosphatase 2A has an essential role in the activation of gamma-irradiation-induced G2/M checkpoint response. Oncogene 2010, 29:4317-4329.
29. Bulavin D.V., Phillips C., Nannenga B., Timofeev O., Donehower L.A., Anderson C.W., Appella E., Fornace A.J. Inactivation of the Wip1 phosphatase inhibits mammary tumorigenesis through p38 MAPK-mediated activation of the p16(Ink4a)-p19(Arf) pathway. Nat. Genet. 2004, 36:343-350.
30. Belova G.I., Demidov O.N., Fornace A.J., Bulavin D.V. Chemical inhibition of Wip1phosphatase contributes to suppression of tumorigenesis. Cancer Biol. Ther. 2005, 4:1154-1158.
31. Harrison M., Li J., Degenhardt Y., Hoey T., Powers S. Wip1-deficient mice are resistant to common cancer genes. Trends Mol. Med. 2004, 10:359-361.
32. Shreeram S., Demidov O.N., Hee W.K., Yamaguchi H., Onishi N., Kek C., Timofeev O.N., Dudgeon C., Fornace A.J., Anderson C.W., Minami Y., Appella E., Bulavin D.V. Wip1 phosphatase modulates ATM-dependent signaling pathways. Mol. Cell 2006, 23:757-764.
33. Macůrek L., Lindqvist A., Voets O., Kool J., Vos H.R., Medema R.H. Wip1 phosphatase is associated with chromatin and dephosphorylates gammaH2AX to promote checkpoint inhibition. Oncogene 2010, 29:2281-2291.
34. van Vugt M.A., Medema R.H. Checkpoint adaptation and recovery: back with Polo after the break. Cell Cycle 2004, 3:1383-1386.
35. van Vugt M.A., Bras A., Medema R.H. Polo-like kinase-1 controls recovery from a G2 DNA damage-induced arrest in mammalian cells. Mol. Cell 2004, 15:799-811.
36. Chow J.P., Poon R.Y. The CDK1 inhibitory kinase MYT1 in DNA damage checkpoint recovery. Oncogene 2013, 32:4778-4788.
37. Chini C.C., Chen J. Human claspin is required for replication checkpoint control. J. Biol. Chem. 2003, 278:30057-30062.
38. Semple J.I., Smits V.A., Fernaud J.R., Mamely I., Freire R. Cleavage and degradation of Claspin during apoptosis by caspases and the proteasome. Cell Death Differ. 2007, 14:1433-1442.
39. Mailand N., Bekker-Jensen S., Bartek J., Lukas J. Destruction of Claspin by SCF-betaTrCP restrains Chk1 activation and facilitates recovery from genotoxic stress. Mol. Cell 2006, 23:307-318.
40. Peschiaroli A., Dorrello N.V., Guardavaccaro D., Venere M., Halazonetis T., Sherman N.E., Pagano M. SCFbetaTrCP-mediated degradation of Claspin regulates recovery from the DNA replication checkpoint response. Mol. Cell 2006, 23:319-329.
41. Strebhardt K., Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat. Rev. Cancer 2006, 6:321-330.
42. Lorca T., Castro A. The Greatwall kinase: a new pathway in the control of the cell cycle. Oncogene 2013, 32:537-543.
43. Yu J., Fleming S.L., Williams B., Williams E.V., Li Z., Somma P., Rieder C.L., Goldberg M.L. Greatwall kinase: a nuclear protein required for proper chromosome condensation and mitotic progression in Drosophila. J. Cell Biol. 2004, 164:487-492.
44. Alvarez-Fernández M., Sánchez-Martínez R., Sanz-Castillo B., Gan P.P., Sanz-Flores M., Trakala M., Ruiz-Torres M., Lorca T., Castro A., Malumbres M. Greatwall is essential to prevent mitotic collapse after nuclear envelope breakdown in mammals. Proc. Natl. Acad. Sci. USA 2013, 110:17374-17379.
45. Peng A., Wang L., Fisher L.A. Greatwall and polo-like kinase 1 coordinate to promote checkpoint recovery. J. Biol. Chem. 2011, 286:28996-29004.
46. Glover D.M. The overlooked greatwall: a new perspective on mitotic control. Open Biol. 2012, 2:120023.
47. Geng L., Zhang X., Zheng S., Legerski R.J. Artemis links ATM to G2/M checkpoint recovery via regulation of Cdk1-cyclin B. Mol. Cell Biol. 2007, 27:2625-2635.
48. Wang H., Zhang X., Geng L., Teng L., Legerski R.J. Artemis regulates cell cycle recovery from the S phase checkpoint by promoting degradation of cyclin E. J. Biol. Chem. 2009, 284:18236-18243.
49. Wierstra I. FOXM1 (Forkhead box M1) in tumorigenesis: overexpression in human cancer, implication in tumorigenesis, oncogenic functions, tumor-suppressive properties, and target of anticancer therapy. Adv. Cancer Res. 2013, 119:191-419.
50. Alvarez-Fernández M., Halim V.A., Krenning L., Aprelia M., Mohammed S, Heck AJ, Medema RH Recovery from a DNA-damage-induced G2 arrest requires Cdk-dependent activation of FoxM1. EMBO Rep. 2010, 11:452-458.
51. Fukumoto Y., Morii M., Miura T., Kubota S., Ishibashi K., Honda T., Okamoto A., Yamaguchi N., Iwama A., Nakayama Y., Yamaguchi N. Src family kinases promote silencing of ATR-Chk1 signaling in termination of DNA damage checkpoint. J. Biol. Chem. 2014, 289:12313-12329.
52. Zhang L., Park C.H., Wu J., Kim H., Liu W., Fujita T., Balasubramani M., Schreiber E.M., Wang X.F., Wan Y. Proteolysis of Rad17 by Cdh1/APC regulates checkpoint termination and recovery from genotoxic stress. EMBO J. 2010, 29:1726-1737.
53. Calonge T.M., O'Connell M.J. Turning off the G2 DNA damage checkpoint. DNA Repair 2008, 7:136-140.
54. Tao R., Xue H., Zhang J., Liu J., Deng H., Chen Y.G. Deacetylase Rpd3 facilitates checkpoint adaptation by preventing Rad53 overactivation. Mol. Cell. Biol. 2013, 33:4212-4224.
55. Vriend L.E., De Witt Hamer P.C., Van Noorden C.J., Würdinger T. WEE1 inhibition and genomic instability in cancer. Biochim. Biophys. Acta 1836, 2013:227-235.
56. Magnussen G.I., Hellesylt E., Nesland J.M., Trope C.G., Flørenes V.A., Holm R. High expression of wee1 is associated with malignancy in vulvar squamous cell carcinoma patients. BMC Cancer 2013, 13:288.
57. Magnussen G.I., Holm R., Emilsen E., Rosnes A.K., Slipicevic A., Flørenes V.A. High expression of Wee1 is associated with poor disease-free survival in malignant melanoma: potential for targeted therapy. PloS One 2012, 7:e38254.
58. Knecht R., Elez R., Oechler M., Solbach C., von Ilberg C., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in squamous cell carcinomas of the head and neck. Cancer Res. 1999, 59:2794-2797.
59. Wolf G., Elez R., Doermer A., Holtrich U., Ackermann H., Stutte H.J., Altmannsberger H.M., Rübsamen-Waigmann H., Strebhardt K. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene 1997, 14:543-549.
60. Feng Y.B., Lin D.C., Shi Z.Z., Wang X.C., Shen X.M., Zhang Y., Du X.L., Luo M.L., Xu X., Han Y.L., Cai Y., Zhang Z.Q., Zhan Q.M., Wang M.R. Overexpression of PLK1 is associated with poor survival by inhibiting apoptosis via enhancement of survivin level in esophageal squamous cell carcinoma. Int. J. Cancer 2009, 124:578-588.
61. Kanaji S., Saito H., Tsujitani S., Matsumoto S., Tatebe S., Kondo A., Ozaki M., Ito H., Ikeguchi M. Expression of polo-like kinase 1 (PLK1) protein predicts the survival of patients with gastric carcinoma. Oncology 2006, 70:126-133.
62. Gray P.J., Bearss D.J., Han H., Nagle R., Tsao M.S., Dean N. Von Hoff DD.Identification of human polo-like kinase 1 as a potential therapeutic target in pancreatic cancer. Mol. Cancer Ther. 2004, 3:641-646.
63. Takahashi T., Sano B., Nagata T., Kato H., Sugiyama Y., Kunieda K., Kimura M., Okano Y., Saji S. Polo-like kinase 1 (PLK1) is overexpressed in primary colorectal cancers. Cancer Sci. 2003, 94:148-152.
64. Wolf G., Hildenbrand R., Schwar C., Grobholz R., Kaufmann M., Stutte H.J., Strebhardt K., Bleyl U. Polo-like kinase: a novel marker of proliferation:correlation with estrogen-receptor expression in human breast cancer. Pathol. Res. Pract. 2000, 196:753-759.
65. Lu L.Y., Yu X. The balance of Polo-like kinase 1 in tumorigenesis. Cell Div. 2009, 4:4.
66. Smith M.R., Wilson M.L., Hamanaka R., Chase D., Kung H., Longo D.L., Ferris D.K. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem. Biophys. Res. Commun. 1997, 234:397-405.
67. Chun G., Bae D., Nickens K., O'Brien T.J., Patierno S.R., Ceryak S. Polo-like kinase1 enhances survival and mutagenesis after genotoxic stress in normal cells through cell cycle checkpoint bypass. Carcinogenesis 2010, 31:785-793.
68. Tsimaratou K., Kletsas D., Kastrinakis N.G., Tsantoulis P.K., Evangelou K., Sideridou M., Liontos M., Poulias I., Venere M., Salmas M., Kittas C., Halazonetis T.D., Gorgoulis V.G. Evaluation of claspin as a proliferation marker in human cancer and normal tissues. J. Pathol. 2007, 211:331-339.
69. Spardy N., Covella K., Cha E., Hoskins E.E., Wells S.I., Duensing A., Duensing S. Human papillomavirus 16 E7 oncoprotein attenuates DNA damage checkpoint control by increasing the proteolytic turnover of claspin. Cancer Res. 2009, 69:7022-7029.
70. Lu X., Nguyen T.A., Moon S.H., Darlington Y., Sommer M., Donehower L.A. The type 2C phosphatase Wip1: an oncogenic regulator of tumor suppressor and DNA damage response pathways. Cancer Metastasis Rev. 2008, 27:123-135.
71. Chen W., Arroyo J.D., Timmons J.C., Possemato R., Hahn W.C. Cancer-associated PP2A A alpha subunits induce functional haploinsufficiency and tumorigenicity. Cancer Res. 2005, 65:8183-8192.
72. Satoh N., Maniwa Y., Bermudez V.P., Nishimura K., Nishio W., Yoshimura M., Okita Y., Ohbayashi C., Hurwitz J., Hayashi Y. Oncogenic phosphatase Wip1 is a novel prognostic marker for lung adenocarcinoma patient survival. Cancer Sci. 2011, 102:1101-1106.
73. Castellino R.C., De Bortoli M., Lu X., Moon S.H., Nguyen T.A., Shepard M.A., Rao P.H., Donehower L.A., Kim J.Y. Medulloblastomas overexpress the p53-inactivating oncogene WIP1/PPM1D. J. Neurooncol. 2008, 86:245-256.
74. Li Z.T., Zhang L., Gao X.Z., Jiang X.H., Sun L.Q. Expression and significance of the Wip1 proto-oncogene in colorectal cancer. Asian Pac. J. Cancer Prev. 2013, 14:1975-1979.
75. Liang C., Guo E., Lu S., Wang S., Kang C., Chang L., Liu L., Zhang G., Wu Z., Zhao Z., Ma S., Wang L., Jiao B.H. Over-expression of wild-type p53-induced phosphatase 1 confers poor prognosis of patients with gliomas. Brain Res. 2012, 1444:65-75.
76. Eichhorn P.J., Creyghton M.P., Bernards R. Protein phosphatase 2A regulatory subunits and cancer. Biochim. Biophys. Acta 2009, 1795:1-15.
77. Nagao M., Shima H., Nakayasu M., Sugimura T. Protein serine/threonine phosphatases as binding proteins for okadaic acid. Mutat. Res. 1995, 333:173-179.
78. Seshacharyulu P., Pandey P., Datta K., Batra S.K. Phosphatase: PP2A structural importance, regulation and its aberrant expression in cancer. Cancer Lett. 2013, 335:9-18.
79. Calin G.A., di Iasio M.G., Caprini E., Vorechovsky I., Natali P.G., Sozzi G., Croce C.M., Barbanti-Brodano G., Russo G., Negrini M. Low frequency of alterations of the alpha (PPP2R1A) and beta (PPP2R1B) isoforms of the subunit A of the serine-threonine phosphatase 2A in human neoplasms. Oncogene 2000, 19:1191-1195.
80. Gartel A.L. A new target for proteasome inhibitors: FoxM1. Expert Opin. Investig. Drugs 2010, 19:235-242.
81. Laoukili J., Stahl M., Medema R.H. FoxM1: at the crossroads of ageing and cancer. Biochim. Biophys. Acta 2007, 1775:92-102.
82. Zhou Z., Jing C., Zhang L., Takeo F., Kim H., Huang Y., Liu Z., Wan Y. Regulation of Rad17 protein turnover unveils an impact of Rad17-APC cascade in breast carcinogenesis and treatment. J. Biol. Chem. 2013, 288:18134-18145.